Viikinkaari 4, FIN-00790 Helsinki, Finland
F +358 9 3193 6554
News archive
01/06/2011
Finland-Based Wireless Network Technology Company Lands in Akron
Akron Mayor Don Plusquellic announced today that Finland-based wireless network technology company, 7signal Ltd., is locating its sales offices and Network Operation Center in Akron’s Biomedical Corridor. “In today’s world of health care,” said the Mayor, “one of the most critical missions is to develop computerized software and hardware that enhances the work of doctors and hospitals.”
23/03/2011
BioFinland prize to Oncos Therapeutics Ltd
Oncolytic viruses are a novel, evolving form of cancer therapy striving toward greater precision, effectiveness, and safety in the treatment of cancer. The biotechnology company Oncos Therapeutics Ltd, operating in Helsinki, works to develop oncolytic viruses on the basis of the results of an experimental therapy programme and years of scientific research carried out at the University of Helsinki. Finnish Bioindustries FIB and the Finnish Fair Foundation have chosen this developer of nextgeneration cancer treatment methods as the recipient of the 2011 BioFinland prize.
07/03/2011
BNCT, a new-generation radiation treatment pioneered in Finland, is effective in advanced head and neck cancer
The years of work done on developing and clinically testing of BNCT – or Boron Neutron Capture Therapy – are now paying off. BNCT-based treatment has been successfully used to treat patients with advanced head and neck cancer who have not responded to previous treatments and generally have poor prognosis.
10/02/2011
MediSapiens gets additional $ 1 million from Tekes to extend its genomic profiling software
February 26, 2011. Helsinki, Finland – MediSapiens, world’s first software company for personalized cancer medicine in oncology clinics and drug development, received approximately $ 1 million (€ 0.75 million) from the Finnish Funding Agency for Technology and Innovation. With the funding, MediSapiens will continue developing its genomics software for biopharmaceutical research and oncology clinics.
03/12/2010
Neurotar offers new insight into CNS-diseases
Neurotar Ltd is the first global commercial provider of high resolution imaging services in a living organism. The company's main focus is on the central nervous system (CNS) and its diseases, such as Alzheimer´s disease, stroke, and migraine. Neurotar´s application of two-photon microscopy to drug discovery and safety studies offers incontestable benefits to pharmaceutical and bio-tech companies.
12/11/2010
Professor Jonathan Knowles acknowledged with Scrip's Lifetime Achievement Award 2010
Professor Jonathan Knowles was acknowledged with Scrip’s Lifetime Achievement Award 2010 for his long academic and commercial career distinguished by a passion for personalised medicine.
07/10/2010
Michael J. Fox Foundation awards $515,086 to professor Mart Saarma for therapeutic development for Parkinson’s disease
HELSINKI, Finland – October 6, 2010 – Hermo Pharma Ltd. today announced that The Michael J. Fox Foundation has awarded a significant research grant to Professor Mart Saarma at the University of Helsinki.
14/09/2010
Labnet Oy and Biofellows Oy joined forces
Two Finnish Life Science distributors, Biofellows and Labnet, joined forces this month and became the largest importer of Life Science products in Finland.
06/08/2010
Lahti and Helsinki science parks strengthen cleantech co-operation through ownership reorganisation
Sitra sells its share in Helsinki Business and Science Park to Lahti Science and Business Park Ltd.Sitra, the Finnish Innovation Fund, has sold its 14% shareholding in Helsinki Business and Science Park (HBSP Ltd) to Lahti Science and Business Park Ltd. Through the transaction, Finland will gain strategic consortia of two significant environmental research and business clusters, which will play an important role in the commercialisation and internationalisation of one of the country's future key pillars – clean technology.
17/06/2010
Oncolytic viruses mediating anti-tumor immunity in human cancer patients published by Oncos Therapeutics and University of Helsinki
Oncos Therapeutics, a biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published today initial results from its Advanced Therapy Access Program in Cancer Research.